Survodutide
Also known as: BI 456906
Profile at a glance
| Attribute | Value |
|---|---|
| Sponsor | Boehringer Ingelheim / Zealand Pharma |
| Mechanism | Dual agonist — GLP-1 + glucagon receptors |
| Administration | Once-weekly subcutaneous injection |
| Peak weight loss | ~18.7% at 46 weeks (Phase 2, 4.8 mg) |
| Status | Phase 3 for obesity and MASH |
Deep dive
What Is Survodutide? The Dual GLP-1/Glucagon Agonist for Weight Loss and MASH →Boehringer Ingelheim's dual GLP-1/glucagon agonist — 18.7% weight loss in Phase 2, 83% MASH resolution, Phase 3 ongoing.
Survodutide compared
Every head-to-head we've published involving Survodutide.
Retatrutide vs Survodutide
Two next-generation obesity drugs that both include glucagon agonism — how the triple and dual agonist approaches compare.
Updated February 2026
Survodutide vs Tirzepatide (Zepbound): Glucagon vs GIP as the Second Target
Survodutide adds glucagon for energy expenditure and liver fat. Tirzepatide adds GIP for insulin and appetite. Different second receptors, different strengths.
Updated February 2026
Mazdutide vs Survodutide: Two GLP-1/Glucagon Dual Agonists Compared
Both target GLP-1 and glucagon, but mazdutide is approved in China with best-in-class tolerability while survodutide leads on MASH liver data.
Updated March 2026
See all drug profiles in the drug profiles hub or compare drugs head-to-head in the comparisons hub.